Like the company’s omicron-focused boosters that were authorized a few months ago, these vaccine candidates are engineered to target omicron subvariants BA.4 and BA.5. As of Dec. 3, BA.5 accounts for 13.8 percent and BA.4 makes up 0 percent of COVID-19 infections. In mid-November, omicron subvariants BQ.1 and BQ.1.1 surpassed the “sister variants” in prevalence.
Currently, Pfizer’s tweaked vaccine is authorized for emergency use in those who are 5 years and older.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
